Expert and Community Perspectives on Attruby for ATTR-Cardiac Amyloidosis (ATTR-CM)

Join us for an insightful 1-hour session to learn more about

The clinical trial data supporting the FDA approval of Attruby for ATTR-cardiac amyloidosis from expert cardiologist Dr. Rola Khedraki

Ken’s journey to diagnosis with
ATTR-cardiac amyloidosis and firsthand experience in a clinical trial for Attruby

BridgeBio’s patient support programs and financial assistance offerings from Patient Access Liaison Director, Heather Polk

webinar date

Thursday, February 20, 2025

6:30 PM – 7:30 PM ET

Meet the Team

What is Attruby?

Attruby is a prescription medicine used to treat adults with a disease that affects the heart muscle called cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), to reduce death and hospitalization related to heart problems.

It is not known if Attruby is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Before taking Attruby, tell your healthcare provider about all your medical conditions, including if you:

are pregnant or plan to become pregnant
are breastfeeding or plan to breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of Attruby?
The most common side effects of Attruby were mild and include:

diarrhea
stomach-area (abdominal) pain

These are not all of the possible side effects of Attruby.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information including Patient Information.

3160 Porter Drive, Suite 250, Palo Alto, CA 94304

Attruby is a trademark and the BridgeBio, Inc. corporate logo is a registered trademark of BridgeBio, Inc.
MAT-US-ACO-0433 V1 01/2025